Leading UK health scientists and institutions will provide insight into successful university spinouts, digital health in the NHS, successful Japan-UK research and commercialisation projects, and academic-industry collaborations.
Dr Jorg Taubel and Dr Ulrike Lorch will be in attendance at this one-day event and presenting to the delegation.
Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD
November 12, 2026
NEJM publication and AASLD presentation reports that 79% of treated participants with MASLD and available measurements achieved normal liver fat levels at Week 24 after a single dose of CIDEBsiRNA, alongside improvements in markers of liver injury.
Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in 14–16 November 2026, on 14–16 November 2026, hosted by the American Heart Association.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
